LOS ANGELES, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) securities between May 17, 2022 and July 19, 2024, inclusive (the “Class Period”). If you suffered a loss on your Allarity investments or would like to inquire about potentiall ...

SAN DIEGO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Allarity Therapeutics, Inc. (NASDAQ: ALLR) securities between May 17, 2022 and July 19, 2024. Allarity is a clinical-stage biopharmaceutical company that develops oncology therapeutics using drug-specific companion diagnostics generated by its Drug Response Predictor technology. For more information, submit a form, emai ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2024. SO WHAT: If you purchased Allarity securities during ...

NEWTOWN, Pa., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a leading class action law firm, announces the recent filing of a securities fraud class action on behalf of purchasers of Allarity Therapeutics, Inc. (NASDAQ: ALLR) common stock between May 17, 2022, and July 19, 2024, inclusive (the “Class Period”). A copy of the Complaint can be found HERE. Investors who purchased Allarity stock may move the U.S. District Court for the Southern District of New York to appoint them as lead plaintiff, n ...

NEW YORK, Sept. 18, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2024.So what: If you purchased Allarity securities during the Class ...

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Allarity securities between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”). ...

Core Viewpoint - Allarity Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its business practices and regulatory compliance during the specified class period from May 17, 2022, to July 19, 2024 [1][2]. Group 1: Legal Proceedings - Investors have until November 12, 2024, to file a lead plaintiff motion in the class action lawsuit [1]. - The lawsuit claims that Allarity and its former officers engaged in improper conduct related to the Dovitinib NDA, which has led to increased regulatory scrutiny and potential legal repercussions [2]. Group 2: Company Misconduct - The complaint asserts that the defendants inflated the regulatory prospects of the Dovitinib NDA and downplayed the likelihood of enforcement actions following the investigation into the company's practices [2]. - This misconduct has exposed Allarity to significant legal, financial, and reputational damages [2].

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Therapeutics, Inc. (“Allarity” or “the Company”) (NASDAQ: ALLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquire ...

Core Viewpoint - A class action lawsuit has been filed against Allarity Therapeutics, Inc. for allegedly misleading investors regarding the regulatory prospects of its Dovitinib NDA, with claims of improper conduct and increased risk of scrutiny [1]. Group 1: Allegations Against Allarity Therapeutics - The lawsuit alleges that Allarity overstated the regulatory prospects of the Dovitinib NDA [1]. - It is claimed that Allarity and three former officers engaged in illegal or improper conduct related to the Dovitinib NDA and Dovitinib-DRP PMA [1]. - The misconduct reportedly increased the risk of regulatory scrutiny and potential enforcement actions, leading to significant legal and reputational harm [1]. - Following the announcement of an investigation into wrongdoing, Allarity allegedly downplayed the likelihood of enforcement actions resulting from the investigation [1]. - As a result, the company's public statements were deemed materially false and misleading throughout the class period [1]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their applications by November 12, 2024 [2]. - Participation in the case is not required to be eligible for recovery; shareholders can remain absent class members if they choose [2]. Group 3: About Robbins LLP - Robbins LLP is a recognized leader in shareholder rights litigation, having recovered over $1 billion for shareholders since its inception in 2002 [3]. - The firm operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless they recover losses [3].

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) securities between May 17, 2022 and July 19, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company’s investors under the ...